Drug Monograph
Alogliptin (Nesina)
alogliptin benzoate
Pharmacokinetic Profile
Half-Life
~21 hours
Metabolism
Minimal (CYP2D6, CYP3A4 contribute); primarily renal excretion
Protein Binding
20%
Bioavailability
~100%
Volume of Distribution
417 L
Clinical Information
Drug Class
DPP-4 Inhibitor
Available Doses
25 mg, 12.5 mg, 6.25 mg tablets
Route
Oral, once daily
Renal Adjustment
Yes — 3-tier (CrCl-based)
Hepatic Adjustment
Not required (mild–moderate); caution with liver disease
Pregnancy
Insufficient data; not recommended
Lactation
Unknown if excreted in human milk
Schedule / Legal Status
Prescription only (not scheduled)
Generic Available
Yes (FDA-approved generic)
Hepatotoxicity Signal
Postmarketing reports of fatal and nonfatal hepatic failure
Indications for Alogliptin
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 2 diabetes mellitus — adjunct to diet and exercise for glycaemic control | Adults (≥18 years) | Monotherapy or combination with metformin, sulphonylurea, thiazolidinedione, or insulin | FDA Approved |
Alogliptin is approved exclusively for improving glycaemic control in adults with type 2 diabetes alongside lifestyle interventions. It is available as a single-entity product (Nesina) and in fixed-dose combinations with metformin (Kazano) and pioglitazone (Oseni). The ADA/EASD 2022 consensus algorithm positions DPP-4 inhibitors as a glucose-lowering option when cost is a consideration and cardiorenal-protective agents (SGLT2 inhibitors, GLP-1 receptor agonists) are not feasible or tolerated.
Off-Label Considerations
Not recommended for type 1 diabetes mellitus. Alogliptin has no approved or well-supported off-label indications. Its use is confined to the single approved indication for T2DM glycaemic management.
Limitations of Use (FDA PI)
It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using alogliptin. Paediatric safety and effectiveness have not been established.
Dosing of Alogliptin
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T2DM — monotherapy (metformin-intolerant or as alternative first-line) | 25 mg once daily | 25 mg once daily | 25 mg/day | Take with or without food; no titration needed Do not split tablets (FDA PI) |
| T2DM — add-on to metformin | 25 mg once daily | 25 mg once daily | 25 mg/day | Metformin dose unchanged Hypo incidence 0% vs 2.9% placebo in add-on to metformin trial |
| T2DM — add-on to sulphonylurea (e.g., glyburide) | 25 mg once daily | 25 mg once daily | 25 mg/day | Consider reducing SU dose to lower hypoglycaemia risk Hypo 9.6% vs 11.1% placebo (add-on to glyburide) |
| T2DM — add-on to pioglitazone (± metformin/SU) | 25 mg once daily | 25 mg once daily | 25 mg/day | Also available as fixed-dose combination (Oseni) Hypo 7.0% vs 5.2% placebo (add-on to pioglitazone) |
| T2DM — add-on to insulin (± metformin) | 25 mg once daily | 25 mg once daily | 25 mg/day | Consider reducing insulin dose; hypo 27% vs 24% placebo Severe hypoglycaemia: 0.8% vs 1.6% placebo |
| T2DM — elderly patients (vs sulphonylurea alternative) | 25 mg once daily | 25 mg once daily | 25 mg/day | Hypo 5.4% vs 26% with glipizide in elderly trial Adjust for renal function; no age-based adjustment needed |
Renal Dose Adjustments
| Renal Function (CrCl) | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Normal or mild impairment (CrCl ≥60 mL/min) | 25 mg once daily | 25 mg once daily | 25 mg/day | No adjustment needed AUC increase ~1.2-fold in mild impairment (not clinically relevant) |
| Moderate impairment (CrCl ≥30 to <60 mL/min) | 12.5 mg once daily | 12.5 mg once daily | 12.5 mg/day | AUC ~2-fold higher than normal renal function |
| Severe impairment (CrCl ≥15 to <30 mL/min) or ESRD (CrCl <15 or on haemodialysis) | 6.25 mg once daily | 6.25 mg once daily | 6.25 mg/day | AUC ~3–4-fold higher; administer without regard to dialysis timing Only ~7% removed by 3 h haemodialysis; not studied in peritoneal dialysis |
Clinical Pearl: Three-Tier Renal Dosing
Unlike some DPP-4 inhibitors with a single renal threshold, alogliptin uses three distinct dose levels matched to CrCl ranges. This provides granular dose individualisation. Assess renal function before initiation and periodically thereafter. The long half-life (~21 h) supports once-daily dosing across all renal strata, and dialysis patients do not require dose-timing coordination with their sessions. Additionally, obtain a liver test panel before starting therapy due to the postmarketing hepatotoxicity signal.
Pharmacology of Alogliptin
Mechanism of Action
Alogliptin is a selective, non-covalent inhibitor of dipeptidyl peptidase-4 (DPP-4) that binds to the enzyme's active site and prevents the degradation of incretin hormones GLP-1 and GIP released from the gut following meals. By extending the circulating half-life of intact incretins, alogliptin augments glucose-dependent insulin secretion from pancreatic beta cells and suppresses inappropriate glucagon release from alpha cells, thereby lowering both fasting and postprandial glucose concentrations. Alogliptin demonstrates high selectivity for DPP-4 over the closely related enzymes DPP-8 and DPP-9 at therapeutic concentrations, which minimises off-target effects. At the recommended 25 mg dose, DPP-4 inhibition exceeds 80% for the full 24-hour dosing interval, supporting once-daily administration. Peak and total GLP-1 exposure increase three- to four-fold compared with placebo.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability ~100%; Tmax 1–2 h; no food effect on AUC or Cmax | Complete oral absorption; can be given with or without food; rapid onset of DPP-4 inhibition |
| Distribution | Vd 417 L (IV data); protein binding 20% | Extensive tissue distribution; low binding means disease-related protein changes will not alter free drug levels |
| Metabolism | Minimal CYP metabolism (CYP2D6, CYP3A4 contribute); 60–71% excreted unchanged in urine; active metabolite M-I <1% of parent; inactive M-II <6% | Negligible hepatic metabolism means no CYP-based dose adjustments and extremely low drug-drug interaction potential |
| Elimination | t½ ~21 h; renal excretion 76%; faecal 13%; renal clearance 9.6 L/h; systemic clearance 14.0 L/h | Long half-life enables true once-daily dosing; predominantly renal elimination mandates dose reduction in CKD; minimally dialysable (~7% over 3 h) |
Side Effects of Alogliptin
≥10%
Very Common (in combination with insulin)
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypoglycaemia (add-on to insulin ± metformin) | 27% (vs 24% placebo; severe: 0.8% vs 1.6%) | Driven by insulin co-therapy; consider proactively reducing insulin dose when adding alogliptin |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nasopharyngitis | 4.8% (vs 4.4% placebo) | Most common adverse reaction; marginal excess over placebo |
| Upper respiratory tract infection | 4.5% (vs 3.5% placebo) | Modest absolute increase; routine monitoring is sufficient |
| Headache | 4.3% (vs 2.9% placebo) | Generally mild and self-limiting |
| Hypoglycaemia (add-on to glyburide) | 9.6% (vs 11.1% placebo) | Lower than placebo arm (which had higher glyburide dose); reduce SU dose if needed |
| Hypoglycaemia (add-on to pioglitazone) | 7.0% (vs 5.2% placebo) | Small excess; monitor when triple therapy includes a sulphonylurea |
| Renal impairment-related adverse reactions (pooled glycaemic trials) | 3.4% (vs 1.3% placebo) | Includes decreased CrCl (1.6%), renal impairment (0.5%), increased creatinine (0.5%) |
| ALT elevations >3× ULN (EXAMINE trial) | 2.4% (vs 1.8% placebo) | Assess liver function at baseline and if hepatic symptoms arise; postmarketing hepatic failure reports exist |
Serious
Serious (regardless of frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Heart failure hospitalization | 3.9% vs 3.3% placebo (EXAMINE; HR 1.19, 95% CI 0.90–1.58) | Variable during follow-up | Evaluate and manage per guidelines; consider discontinuation; greatest concern in patients without prior HF (2.2% vs 1.3%, p=0.03) |
| Acute pancreatitis | 0.4% vs 0.3% placebo (EXAMINE); 0.2% vs <0.1% (glycaemic trials) | Any time during therapy | Discontinue immediately; do not rechallenge; initiate supportive care |
| Hepatic failure (fatal and nonfatal) | Rare (postmarketing); causality not excluded | Variable | Check liver tests if symptoms arise (fatigue, anorexia, jaundice, dark urine); discontinue if significant ALT elevation confirmed; do not restart if liver injury confirmed without alternative explanation |
| Anaphylaxis / angioedema / Stevens-Johnson syndrome | Rare (postmarketing) | Variable; may occur at any time | Discontinue permanently; emergency care; switch to alternative antidiabetic therapy |
| Bullous pemphigoid | Rare (DPP-4 class effect, postmarketing) | Months to years | Discontinue; dermatology referral for immunosuppressive treatment |
| Severe and disabling arthralgia | Rare (DPP-4 class effect, postmarketing) | 1 day to years after initiation | Consider discontinuation; symptoms resolve on withdrawal; may recur with rechallenge |
| Tubulointerstitial nephritis | Very rare (postmarketing) | Variable | Discontinue; nephrology referral; assess renal function |
| Rhabdomyolysis | Very rare (postmarketing) | Variable | Check CK; discontinue; intravenous fluids; monitor renal function |
Discontinuation
Discontinuation Rates
Alogliptin 25 mg (pooled 14 controlled trials, N=6447)
6.8% vs 8.4% placebo
Key finding: Discontinuation rate was actually lower than placebo, suggesting good overall tolerability
Active Comparator Arms
6.2%
Context: Alogliptin discontinuation was similar to active comparators, indicating tolerability comparable to standard antidiabetic options
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Overall adverse reactions | 6.8% | Lower than placebo (8.4%); overall adverse event rate was 73% vs 75% placebo |
| Renal impairment-related events | Not individually reported | Aggregate renal AEs were 3.4% alogliptin vs 1.3% placebo; individual reasons not broken down for discontinuation |
Managing the Hepatotoxicity Signal
Alogliptin is unique among DPP-4 inhibitors in carrying a specific FDA warning for hepatic effects, including postmarketing reports of fatal hepatic failure. While the causal relationship cannot be definitively established, clinicians should obtain baseline liver tests before initiating therapy. If a patient reports unexplained fatigue, loss of appetite, right upper abdominal discomfort, dark urine, or jaundice, liver function should be checked promptly. If clinically significant ALT elevations persist or worsen, alogliptin should be discontinued and not restarted unless an alternative explanation for the liver injury is identified.
Drug Interactions with Alogliptin
Alogliptin is primarily eliminated renally with negligible CYP-mediated metabolism. It is neither an inducer nor inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations. This translates to an exceptionally clean drug interaction profile — no significant pharmacokinetic interactions have been identified in clinical studies with any tested CYP substrate, CYP inhibitor, or renally excreted drug.
Moderate
Insulin / Sulphonylureas
MechanismPharmacodynamic synergy: combined insulin-secretory effects
EffectIncreased hypoglycaemia risk; 27% with insulin vs 24% placebo; 9.6% with glyburide vs 11.1% placebo
ManagementConsider proactively reducing insulin or SU dose when initiating alogliptin; educate patient on hypoglycaemia recognition
FDA PI
Minor
Metformin
MechanismNo pharmacokinetic interaction (both renally excreted but via different mechanisms)
EffectNo meaningful change in exposure of either drug
ManagementNo dose adjustment; safe to combine (available as fixed-dose Kazano)
FDA PI
Minor
Pioglitazone
MechanismNo pharmacokinetic interaction
EffectNo clinically meaningful change in exposure of either drug
ManagementNo dose adjustment; available as fixed-dose Oseni
FDA PI
Minor
Warfarin
MechanismNo CYP2C9 inhibition or induction
EffectNo effect on warfarin PK, prothrombin time (PT), or INR
ManagementNo dose adjustment of warfarin; no additional INR monitoring beyond standard of care
FDA PI
Minor
CYP Inhibitors (ketoconazole, fluconazole, gemfibrozil)
MechanismAlogliptin undergoes negligible CYP metabolism; inhibiting CYP has minimal effect
EffectNo clinically meaningful changes in alogliptin exposure
ManagementNo dose adjustment required — unlike saxagliptin, no dose reduction needed with CYP3A4 inhibitors
FDA PI
Minor
Cyclosporine, Digoxin, Atorvastatin, Oral Contraceptives, Cimetidine
MechanismAlogliptin does not inhibit/induce CYPs or P-gp; no competition for renal secretion at clinical doses
EffectNo clinically significant changes in exposure for any tested agent
ManagementNo dose adjustments needed for any of these agents
FDA PIMonitoring for Alogliptin
-
HbA1c
Baseline, then every 3–6 months
Routine Primary efficacy measure. Expect placebo-corrected A1C reduction of 0.4–0.6% as monotherapy, 0.5–0.7% with metformin combination. Target individualised per ADA guidelines. -
Renal Function (CrCl)
Before initiation, then periodically
Routine Required to select appropriate dose tier (25 mg / 12.5 mg / 6.25 mg). Renal impairment-related AEs were 3.4% vs 1.3% placebo in glycaemic trials. -
Liver Function Tests
Baseline; then if symptoms arise
Routine Unique to alogliptin among DPP-4 inhibitors: postmarketing reports of fatal and nonfatal hepatic failure. Measure liver tests promptly if fatigue, anorexia, RUQ discomfort, dark urine, or jaundice develops. ALT >3× ULN was 2.4% vs 1.8% placebo in EXAMINE. -
Heart Failure Signs
Each visit
Routine EXAMINE showed HF hospitalization of 3.9% vs 3.3% placebo (HR 1.19, not statistically significant). FDA issued heart failure warning in April 2016 for alogliptin-containing products. -
Pancreatitis Symptoms
Each visit; patient education
Routine Instruct patients about severe persistent abdominal pain radiating to the back. Reported in 0.4% vs 0.3% in EXAMINE. -
Skin Integrity
Each visit; patient self-monitoring
Trigger-based Watch for blisters or erosions suggestive of bullous pemphigoid (DPP-4 class effect); also monitor for severe cutaneous reactions including Stevens-Johnson syndrome. -
Joint Pain Assessment
At follow-up visits
Trigger-based Severe and disabling arthralgia is a DPP-4 class effect. Time to onset ranges from 1 day to years. Symptoms typically resolve on discontinuation.
Contraindications & Cautions for Alogliptin
Absolute Contraindications
- History of serious hypersensitivity reaction to alogliptin or any excipient, including anaphylaxis, angioedema, or severe cutaneous adverse reactions such as Stevens-Johnson syndrome (FDA PI).
- Type 1 diabetes mellitus — alogliptin is not effective and not indicated for this condition.
Relative Contraindications (Specialist Input Recommended)
- Active liver disease or unexplained persistent ALT elevation — due to postmarketing reports of fatal hepatic failure; obtain baseline liver tests and avoid initiating if significant hepatic dysfunction is present. Alogliptin has not been studied in severe hepatic impairment (Child-Pugh C).
- History of heart failure or high HF risk — EXAMINE showed a numerical (non-significant) increase in HF hospitalization; significant increase in patients without prior HF (2.2% vs 1.3%, p=0.03). FDA issued a heart failure warning in 2016.
- History of pancreatitis — unknown whether such patients are at increased risk; discuss alternatives.
- Prior angioedema with another DPP-4 inhibitor — cross-reactivity is unknown; use with extreme caution.
Use with Caution
- Moderate-to-severe renal impairment — dose reduction mandatory (12.5 mg for CrCl 30–<60; 6.25 mg for CrCl <30 or ESRD).
- Elderly patients (≥65 years) — no specific dose adjustment, but assess renal function more frequently due to age-related CrCl decline.
- Concomitant insulin or sulphonylureas — increased hypoglycaemia risk; proactive dose reduction of the secretagogue or insulin recommended.
FDA Safety Communication
Heart Failure Risk with Alogliptin
In April 2016, the FDA added warnings to the labelling of alogliptin-containing products regarding an increased risk of heart failure. In the EXAMINE trial, 3.9% of alogliptin-treated patients were hospitalised for heart failure compared to 3.3% on placebo (HR 1.19; 95% CI 0.90–1.58). While this did not reach statistical significance overall, a subgroup analysis showed a significant increase in patients without prior heart failure history (2.2% vs 1.3%, p=0.03). Clinicians should weigh risks and benefits before initiating alogliptin in patients with known HF risk factors.
Patient Counselling for Alogliptin
Purpose of Therapy
Alogliptin helps control blood sugar levels in type 2 diabetes by enhancing the body's own insulin response after meals. It works in a glucose-dependent manner, meaning it carries a low risk of causing dangerously low blood sugar when used on its own or with metformin.
How to Take
Take one tablet once daily at the same time each day, with or without food. Do not split the tablet. If a dose is missed, take it as soon as remembered; if close to the next dose, skip the missed dose and resume the regular schedule — do not double up.
Liver Problems
Tell patient
Rare cases of serious liver problems have been reported with alogliptin. Your doctor will check your liver function before starting this medicine.
Call prescriber
Contact your doctor immediately if you develop unexplained tiredness, loss of appetite, upper-right abdominal pain, dark urine, or yellowing of skin or eyes (jaundice).
Pancreatitis
Tell patient
Acute inflammation of the pancreas has been reported with this class of medications. Learn the key symptom: severe, persistent pain in the upper abdomen that may spread to the back, with or without vomiting.
Call prescriber
Stop taking alogliptin and seek urgent medical attention if this type of abdominal pain develops.
Heart Failure Symptoms
Tell patient
In a large clinical trial, there was a small numerical increase in heart failure hospitalisations with alogliptin. Awareness of warning signs is important.
Call prescriber
Report increasing breathlessness (especially lying down), rapid unexplained weight gain, or new swelling of ankles or feet promptly.
Allergic Reactions
Tell patient
Serious allergic reactions including facial or throat swelling, rash, skin peeling, and difficulty breathing have been reported.
Call prescriber
Stop alogliptin and seek emergency care immediately if swelling of face, lips, tongue, or throat occurs, or if skin blistering or peeling develops.
Low Blood Sugar Risk with Certain Combinations
Tell patient
Low blood sugar is more likely if alogliptin is taken with insulin or a sulphonylurea. Know the signs: shaking, sweating, fast heartbeat, dizziness, hunger, and confusion.
Call prescriber
Contact your healthcare team if low blood sugar episodes are frequent or severe. The insulin or sulphonylurea dose may need to be lowered.
Joint Pain & Skin Blisters
Tell patient
Some patients on DPP-4 inhibitors have developed severe joint pain or a skin blistering condition. These can occur at any time during treatment.
Call prescriber
Report new severe joint pain or unexplained skin blisters/erosions promptly.
Sources
Regulatory (PI / SmPC)
- Takeda Pharmaceuticals America, Inc. NESINA (alogliptin) tablets, for oral use. Full Prescribing Information. Revised 03/2022. FDA Label Primary regulatory source for all dosing, adverse reaction incidences, pharmacokinetic parameters, and contraindication statements in this monograph.
- FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. April 5, 2016. FDA Safety Communication Regulatory basis for the heart failure warning added to alogliptin labelling based on EXAMINE trial findings.
Key Clinical Trials
- White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi:10.1056/NEJMoa1305889 Primary EXAMINE trial publication demonstrating cardiovascular safety (non-inferiority for MACE) of alogliptin in post-ACS patients with T2DM.
- Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076. doi:10.1016/S0140-6736(14)62225-X Detailed heart failure analysis from EXAMINE showing no overall significant increase in HF hospitalization but a signal in patients without prior HF.
- White WB, Kupfer S, Zannad F, et al. Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial. Diabetes Care. 2016;39(7):1267–1273. doi:10.2337/dc16-0303 CV mortality analysis from EXAMINE showing similar rates between alogliptin (4.1%) and placebo (4.9%).
- DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care. 2008;31(12):2315–2317. doi:10.2337/dc08-1035 Early dose-ranging study establishing the efficacy of alogliptin 25 mg daily for glycaemic control in T2DM.
Guidelines
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S321. doi:10.2337/dc24-SINT Current ADA guidelines positioning DPP-4 inhibitors in the treatment hierarchy, primarily when cost is a factor and cardiorenal benefit is not the primary agent-selection driver.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034 ADA/EASD consensus algorithm placing DPP-4 inhibitors below SGLT2 inhibitors and GLP-1 RAs when cardiorenal protection is desired.
Mechanistic / Basic Science
- Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007;50(10):2297–2300. doi:10.1021/jm070104l Discovery chemistry paper describing the rational design of alogliptin as a highly selective, non-covalent DPP-4 inhibitor.
- Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513–527. doi:10.1016/j.clinthera.2008.03.005 First-in-human PK/PD study demonstrating dose-proportional exposure, >93% DPP-4 inhibition at 25 mg, and ~21-hour half-life.
Pharmacokinetics / Special Populations
- Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499–512. doi:10.1016/j.clinthera.2008.03.004 Multiple-dose PK study in T2DM patients confirming minimal accumulation, sustained DPP-4 inhibition >80% at 24 hours, and dose-proportional pharmacokinetics.
- Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648–658. doi:10.1111/j.1463-1326.2010.01212.x Comparative pharmacokinetic review of all DPP-4 inhibitors highlighting alogliptin's unique profile: 100% bioavailability, 21-hour half-life, and negligible CYP metabolism.
- Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501–514. doi:10.1007/BF03261927 Cross-class PK comparison useful for understanding alogliptin's positioning versus sitagliptin, saxagliptin, and linagliptin in terms of metabolism, renal handling, and drug interactions.